MyrnaRitaNahasMD

PubMed

• A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
  Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen
  Clinical Lymphoma, Myeloma & Leukemia. 2024-05-01
• 1 citations
  Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.
  John Gribben, M Lia Palomba, Anik R Patel, Myrna Nahas, Sattva S Neelapu
  Blood Advances. 2023-06-13
• 13 citations
  Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.
  Paola Ghione, M Lia Palomba, Hervé Ghesquieres, Sabela Bobillo, Anik R Patel
  Haematologica. 2023-03-01

Abstracts/Posters

• T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy
  Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
  Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
  Myrna Nahas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019